Lv6
2420 积分 2022-05-24 加入
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial
2小时前
已完结
The value of anti-CD30 CAR T cells in Hodgkin lymphoma
15天前
已完结
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high‐risk or relapsed/refractory non‐Hodgkin's lymphomas
22天前
已完结
Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia
24天前
已完结
The value of anti-CD30 CAR T cells in Hodgkin lymphoma
29天前
已完结
Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development
2个月前
已完结
How I Treat patients with AML using azacitidine and venetoclax
2个月前
已完结
How I Treat patients with AML using azacitidine and venetoclax
2个月前
已关闭
How I Treat patients with AML using azacitidine and venetoclax
2个月前
已关闭
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
2个月前
已完结
皖公网安备34019202002308
